Could Single-Cell RNA Sequencing Help Personalize Multiple Myeloma Treatment?

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights research that found that single-cell RNA sequencing can better characterize patients and potentially improve multiple myeloma treatment in a more personalized manner.

In this video, Samir Parekh, MD, of Icahn School of Medicine at Mount Sinai in New York, highlights a study that shows that patients with relapsed multiple myeloma may need highly individualized therapy to overcome the complexity of relapsed disease. The researchers found that single-cell RNA sequencing can better characterize patients and potentially improve treatment in a more personalized manner.

Results of the study (abstract 62) were presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

Roman Fabbricatore
February 4th 2025
Article

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Ariana Pelosci
January 24th 2025
Article

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

ONCOLOGY Staff
January 1st 2025
Article

A Satellite Sessions event that took place at Fred Hutchinson Cancer Center and discussed treatments surrounding LCL and CLL.